CME Presentations

Pediatric Neuroblastoma



  • Shakeel Modak, MD, MRCP

    Shakeel Modak, MD, MRCP

    Shakeel Modak, MD, MRCP

    Acting Chief, Neuroblastoma Service

    Shakeel Modak, MD, MRCP, is a pediatric hematologist/oncologist and acting chief of neuroblastoma at Memorial Sloan Kettering Cancer Center (MSKCC), and professor of pediatrics at Weill Cornell Medical College in New York City. His research interests are in immunotherapy of neuroblastoma and radioimmunotherapy of pediatric solid tumors. Dr Modak received his medical degree and completed his pediatric residency at Topiwala National Medical College in Bombay, India. He completed his fellowship in pediatric hematology/oncology at MSKCC.
  • Rachel Glincher, RN, MSN, CPNP-AC, CPHON

    Rachel Glincher, RN, MSN, CPNP-AC, CPHON

    Rachel Glincher, RN, MSN, CPNP-AC, CPHON

    Pediatric Nurse Practitioner

    Rachel Glincher, RN, MSN, CPNP-AC, CPHON, is a pediatric nurse practitioner at Memorial Sloan Kettering Cancer Center in New York, New York. She has presented both nationally and internationally on the care of children with cancer. Rachel graduated from the University of Pennsylvania in Philadelphia with her master’s and started her nursing career as a staff nurse at Maimonides Medical Center in Brooklyn, New York. She completed the Robbie Simpson Fellowship at St. Jude Children’s Research Hospital in Memphis, Tennessee in 2015.
  • Gregory Sizikov

    Gregory Sizikov

    Gregory Sizikov

    Pediatric Neuroblastoma Parent

    Pediatric Neuroblastoma Parent
  • Donna Ludwinski

    Donna Ludwinski

    Donna Ludwinski

    Director of Research Advocacy

    Donna Ludwinski is active as a research advocate since her son, Erik, battled neuroblastoma (diagnosed in 1991 and died in 2010 at age 24). She tracks clinical research on pediatric cancers and attends major oncology conferences to keep abreast of promising research advances. Donna serves on the NCI Pediatric Central Review Board, FDA Patient Representative for Advisory Committees, New Approaches to Neuroblastoma Therapy (NANT) Advisory Council, and "Fit For Filing" Working Group for ACCELERATE. Recently, she served on the AACR Pediatric Working Group Steering Committee, and Board of Directors of Coalition Against Childhood Cancer (CAC2). Donna is passionate about advocating for families dealing with childhood cancer. She lives in West Virginia with her husband Paul and youngest son Aron.

CME Information

Management of High-Risk Relapsed/Refractory Pediatric Neuroblastoma: Novel Agents and Patient Perspectives for Advanced Practitioners

Global Logo PQH Logo


After completing this activity, the participant should be better able to:
  • Summarize the mechanisms of action of emerging agents for relapsed/refractory high-risk neuroblastoma
  • Describe strategies to manage challenges of administration and treatment-related adverse effects in patients undergoing treatment for relapsed/refractory high-risk neuroblastoma
  • Facilitate communication with patients, caregivers, and families in navigating treatment options, side-effect management, and care coordination
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with Solving Kids’ Cancer.


This activity is supported by an educational grant from Y-mAbs Therapeutics, Inc.


This activity was released on December 4, 2020 and is valid for 12 months. Requests for credit must be made no later than December 4, 2021.


The educational design of this activity addresses the needs of pediatric oncology nurses, advanced practice providers (including nurse practitioners and physician assistants), pediatric oncologists, social workers, and other members of the team caring for children with pediatric neuroblastoma.


Advanced practitioners have a vital role to play in the care of neuroblastoma, The most common extracranial solid tumor in childhood, with about 700 new cases in the US each year among children 14 and younger. Ad Immunotherapy promises to address a number of unmet therapeutic needs and improve the prognosis for patients with relapsed/refractory high-risk neuroblastoma.

Join a multidisciplinary panel of experts and patient advocates led by Dr. Shakeel Modak as they discuss emerging treatment options, including anti-GD2 agents, for high-risk relapsed/refractory pediatric neuroblastoma. Panelists will also review the determination of risk status, patient-selection criteria, and strategies to address adverse effects throughout the course of treatment. Learn strategies to educate and improve communication with patients, families, and caregivers from a patient advocate and parent on the panel to ensure greater care coordination.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 1 hour to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Shakeel Modak, MD
Acting Chief, Neuroblastoma Service
Attending, Pediatrics
Memorial Sloan Kettering Cancer Center
Consultant/Independent Contractor: Illumina Radiopharmaceuticals, Y-mAbs Therapeutics, Inc. Grant/Research Support: Roche/Genentech Advisory Board: Progenics
Rachel Glincher, RN, MSN, CPNP-AC, CPHON
Pediatric Nurse Practitioner
Memorial Sloan Kettering Cancer Center
Other/Royalties: Rachel has no personal financial relationships. She works at Memorial Sloan Kettering Cancer Center (MSK) and MSK has institutional financial interests related to this research in the form of intellectual property rights and equity interests in Y-mAbs, the company licensing the intellectual property from MSK.
Donna Ludwinski
Director of Research Advocacy
Solving Kids’ Cancer
Nothing to disclose
Gregory Sizikov
Caregiver Panelist
Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
Jaume Mascaro Nothing to disclose
Emma Mayo Nothing to disclose
Helen McCarthy-Tennant Consultant/Independent Contractor: YmAbs Therapeutics, Inc.
Ashley Marostica, RN, MSN Nothing to disclose
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Jaimee Harris-Gold Nothing to disclose
Tariqa Ackbarali Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at